Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.74 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538661 | 0.85 | NR3C2 (0.65) | PTGS2NR3C2PTGS1 | |
| SCHEMBL4539672 | 0.77 | NR3C2 (1.00) | PTGS2NR3C2PTGS1 | |
| SCHEMBL4537960 | 0.77 | NR3C2 (0.58) | PTGS2NR3C2 | |
| SCHEMBL4587051 | 0.76 | PTGS2 (0.73) | PTGS2PTGS1CYP3A4CYP2C9TSHR | |
| SCHEMBL8265772 | 0.76 | PTGS2 (0.73) | PTGS2PTGS1CYP3A4CYP2C9TSHR | |
| SCHEMBL8917353 | 0.76 | PTGS2 (0.68) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18448102 | 0.76 | PTGS2 (0.72) | PTGS2PTGS1CYP3A4CYP2C9TSHR | |
| SCHEMBL27602805 | 0.75 | PTGS1 (0.82) | PTGS2PTGS1 | |
| SCHEMBL7113078 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5229949 | 0.74 | PTGS2 (1.00) | PTGS2PTGS1CYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2638012-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, AVPR2 | PTGS2 732/4885NR3C2 1/4885PTGS1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.